Skip to main content
Bentham Open Access logoLink to Bentham Open Access
. 2023 Apr 4;26(8):1560–1570. doi: 10.2174/1386207326666221031122803

Molecular Mechanisms of Notopterygii rhizoma Et Radix for Treating Arrhythmia Based on Network Pharmacology

Penglu Wei 1, Juju Shang 1,*, Hongxu Liu 1,*, Wenlong Xing 1, Yupei Tan 1,2
PMCID: PMC10242764  PMID: 36321231

Abstract

Objective

To explore the possible mechanism for treating NRR in arrhythmia using network pharmacology and molecular docking in this study.

Methods

Active compounds and targets for NRR were retrieved from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) Database and Analysis Platform, SymMap, and the Encyclopedia of Traditional Chinese Medicine (ETCM) databases. Arrhythmia-related genes were acquired from the Comparative Toxicogenomics Database (CTD) and the GeneCards database. Overlapping targets of NRR associated with arrhythmia were acquired and displayed via a Venn diagram. DAVID was applied for GO and KEGG pathway analyses. Cytoscape software and its plug-in were used for PPI network construction, module division and hub nodes screening. AutoDock Vina and qRT-PCR were carried out for validation.

Results

In total, 21 active compounds and 57 targets were obtained. Of these, coumarin was the predominant category which contained 15 components and 31 targets. There were 5 key targets for NRR in treating arrhythmia. These targets are involved in the apoptotic process, extrinsic apoptotic signaling pathway in the absence of ligand, and endopeptidase activity involved in the apoptotic process by cytochrome c. The main pathways were the p53 signaling pathway, Hepatitis B and apoptosis. The molecular docking and qRT-PCR displayed good effects on hub node regulation in NRR treatment.

Conclusion

NRR plays an important role in anti-apoptotic mechanisms that modulate the p53 signaling pathway, which may provide insight for future research and clinical applications focusing on arrhythmia therapy.

Keywords: Notopterygii rhizoma Et radix, arrhythmia, molecular mechanisms, network analysis, molecular docking, traditional chinese medicine

1. INTRODUCTION

Ventricular arrhythmias are a major cause of morbidity and mortality in patients with heart disease [1]. It can manifest as asymptomatic premature ventricular contractions (PVCs) or non-sustained ventricular tachycardia (VT), and its symptoms include arrhythmia, or continuous ventricular tachycardia, ranging from patients presenting with mild symptoms to complete hemodynamics collapse [2, 3]. Medications, catheter ablation, or an embedded cardioverter-defibrillator can be used to treat arrhythmias. Unfortunately, many patients are prone to recurrence after surgery, and their symptoms persist [3]. Complementary and alternative therapies have unique advantages and potential in treating arrhythmias [4]. Different from the past model of “single-gene, single-target and single-drug,” the characteristic of the “multi-component, multi-target and multi-pathway” of traditional Chinese medicine has promoted the transformation of the drug discovery paradigm [5, 6]. Notopterygii rhizoma et Radix (NRR) is an important constituent of traditional Chinese medicine [7]. It is derived from the dried roots and rhizomes of Notopterygium incisum Ting ex H. T. Chang (N. incisum) and Notopterygium franchetii H. de Boiss. (N. franchetii), belonging to the Apiaceae family [8]. Many experiments have shown that NRR can help prevent arrhythmia [9-11]; however, its mechanisms are still unclear.

Currently, the main approaches of drug design include pharmacophore linking strategy [12], structure-based and ligand-based [13, 14], and fragment-based [15] drug discovery. In addition, molecular databases [16] (such as Protein Data Bank database, KEGG database, Comparative Toxicogenomics database, PubChem Bioassay database, etc.) and computer-aided [17, 18] (such as artificial intelligence) methods can be used for pharmacological studies. The related studies of Chinese herbs and formulas are increasing [19, 20]. In this study, we combined systems biology, network pharmacology, molecular docking, and experimental validation to elucidate the possible mechanism of action of the drugs. The flowchart of this research is shown in (Fig. 1).

Fig. (1).

Fig. (1)

Network pharmacology for deciphering pharmacological mechanisms of NRR in treating arrhythmia.

2. MATERIALS AND METHODS

2.1. Screening of Active Ingredients

The Traditional Chinese Medicine Systems Pharmacology (TCMSP, https://tcmspw.com/index.php) Database and Analysis Platform, SymMap (http://www.symmap.org/), and the Encyclopedia of Traditional Chinese Medicine (ETCM, http://www.tcmip.cn/ETCM/index.php/Home/Index/) databases were searched to collate information regarding each of the chemical compounds within NRR [21-23]. The effective compounds were filtered based on their pharmacokinetic properties, including oral bioavailability (OB) ≥30% and drug-likeness (DL) index ≥0.18. Furthermore, the two/three-dimensional (2/3D) structures, canonical smiles and PubChem ID of the active compounds were acquired using the PubChem (https://pubchem.ncbi.nlm.nih.gov/) database. The resulting data was standardized using the Universal Protein Database (UniProt, https://www.uniprot.org/). The Protein Data Bank identification (PDB ID) was acquired from the database of PDB (https://www.rcsb.org/).

2.2. Identification of Arrhythmia-associated Targets and Collection of Putative Target Proteins

The Comparative Toxicogenomics Database (CTD, http://ctdbase.org/) [24] and GeneCards (https://www.gene cards.org/) [25] databases were applied to identify potential targets relating to arrhythmia, including ventricular premature beat (VPB), VT and ventricular fibrillation (Vf). Arrhythmia-associated genes were screened using scores >50% of CTD and 30% of GeneCards as cutoffs, respectively. The candidate targets for NRR and arrhythmia were further used and pooled to enable Venn analysis, which was used to obtain the targets for NRR-achieved anti-arrhythmia.

2.3. Construction of Protein-Protein Interaction (PPI) Network and Topological Analysis

The merged targets of NRR and arrhythmia were used to construct a PPI network via search tools for recurring instances of neighboring genes (STRING) database (v11.5) (https://www.string-db.org/). These used active interaction sources from text mining, experiments, databases, co-expression, neighborhood and gene fusion, and the raw data were saved in a tab-separated values (TSV) format. The Analyze Network tool of Cytoscape 3.8.2 was used to calculate the topological parameter [26]. The plugin MCODE (molecular complex detection) was used for module division; CytoHubba was applied to detect the core targets based on the maximal clique centrality (MCC) algorithm.

2.4. GO and KEGG Enrichment

The GO (Gene Ontology) and KEGG (Kyoto Encyclopedia of Genes and Genomes) enrichment analysis of overlapping target and core targets were carried out through the Database for Annotation, Visualization and Integrated Discovery (DAVID) v6.8 (https://david.abcc.ncifcrf.gov/) [27-28]. The following settings were applied: background and species = Homo sapiens, expression analysis systematic explorer = 0.01 and count = 2. P < 0.05 indicated a statistically significant difference in the annotation categories.

2.5. Molecular Docking

Small molecule ligand 2D structures of key active compounds were obtained from the PubChem database (https://pubchem.ncbi.nlm.nih.gov) and saved in an SDF format. These were then converted into 3D structures and optimized using the ChemBio3D Draw module in Chem Bio Office2010 software. Crystal structures of the five core receptors were downloaded from the PDB. The filter criteria were set as follows: (1) the protein structure is obtained by X-crystal diffraction; (2) preferential selection of protein structures reported in the literature of molecular docking; (3) the organism comes from Homo sapiens. The protein visualization software Pymol (v2.0) was used to remove ligand and water motifs. The AutoDockTools (v1.5.6) software was applied to process proteins, including adding nonpolar hydrogen, calculating the Gasteiger charge, assigning the AD4 type, and setting all the flexible bonds of small molecule ligands to be rotatable. Then the docking box was modulated based on the original ligand coordinates. Furthermore, the receptor protein was set as rigid docking, the genetic algorithm was selected, and the maximum number of evals was set as the medium. The docking results were acquired by running autogrid4 and autodock4, revealing the binding energies. The partial diagrams of molecular docking were then produced using the Pymol.

2.6. Experimental Validation

2.6.1. Experimental Model and Drug Treatment

NRR granular was purchased from the Granule Dispensing Department of Dongzhimen Hospital, Beijing University of Chinese Medicine. Calcium chloride was purchased from Sino Animal(Beijing)Science and Technology Development Co. Ltd (Beijing, China).

The experimental procedures used in this study were approved by the Animal Welfare Ethics Committee of Sino Animal (Beijing) Science and Technology Development Co. Ltd. and were per the U.S. National Institutes of Health (NIH) guidelines (Publications No. 8023). Eighteen 8-week-old SD male rats were obtained from SPF (Beijing) Biotechnology Co., Ltd. [experimental animal license No. SYXK (Beijing), 2020-00 51]. The rats were placed in polycarbonate cages under a 12-h light/dark cycle, in an air-conditioned room, under a constant temperature (25 ± 1 °C) and humidity (50 ± 10%), with an SPF grade. The 18 mice were randomly divided into three groups: sham (deionized water), vehicle (deionized water) and NRR (NRR granule,19.08 mg/100g, 0.5ml/100g). Following a 14-day gavage period, on the 14th day, the rats were anesthetized for 30 minutes via intragastric administration. Anesthesia was induced via inhalation of 4% isoflurane and maintained with 2% isoflurane, and then linked electrocardiograph (ECG) leads were positioned. The IV lead electrocardiogram output was recorded using the PowerLab biological signal processing system. Once the electrocardiogram had stabilized, the sham rats were each injected with saline (0.9% NaCl, 1.5ml/min/kg) through the tail vein. The vehicle and NRR rats were injected with a calcium chloride solution (1.5ml/min/kg, concentration 35mg/ml) via the tail vein. The electrocardiogram output was recorded for 10 min, and arrhythmia was observed. The left cardiac myocardium (left ventricle) was frozen for analysis.

2.6.2. Quantitative Real-time PCR

Five rats from each group were used for qRT-PCR experiments. Total RNA was extracted from the left cardiac myocardium using TRIzol (Tiangen Biochemical Technology, Beijing, Co., Ltd) and reverse transcribed into cDNA using a reverse transcription system kit (Takara, Shanghai, China) per the manufacturer’s protocol. qRT-PCR was performed on an ABI 7500 Real-Time PCR System (Applied Biosystems, Foster City, USA) using the SYBR Green PCR Kit to determine mRNA expression levels. The relative expression levels of CASP3 (primers: GCGGTATTGAGACAGACAGTGGA and ACGAGTGAGGATGTGCATGAATT), CASP8 (primers: TTTCTGTTTTGGATGAGGTGAC and ATGTTGCTGAGTTTGGGTATGT), CASP9 (primers: GCGACATGATCGAGGATATTC and CAGGTGGTCTA GGGGTGTAAC), BAX (primers: GGTGGTTGCCCTTT TCTACTTTGC and GCTCCCGGAGGAAGTCCAGTG), CDK2 (primers: CCCTGTCCGTACTTACACTCAT and CTTGGGGAAACTTGGCTTATA) were analyzed using the comparative CT method for relative quantitation and the 2-DDCt method, which involved the levels against β-actin expression. The relative expression data was presented as a percentage change compared to the matched controls. All of the quantitative data, obtained from at least three independent experiments, were presented as the mean ± standard error of the mean. SPSS statistical software version 27.0 (IBM Corp., Armonk, NY, USA) was used for statistical analysis. Student’s t-test was used to compare two groups, whereas a one-way analysis of variance was used to compare all three groups. P values lower than 0.05 were considered statistically significant.

3. RESULTS

3.1. Active Compounds and Target Genes Detection

185, 235 and 58 components were obtained from the TCMSP, SymMap and ETCM databases, respectively. After their pharmacokinetic properties were screened and duplications removed, 21 active components remained. These were divided into five categories: 15 coumarins (e.g., Cnidilin, Ammidin, Phellopterin, etc.), 1 flavonoid (Diosmetin), 1 nitrogen-containing compound (Isoindigo), 2 triterpenoids (beta-sitosterol and Sitosterol) and 2 others (Fig. 2). The details of the 21 compounds are presented in Table S1 (659.3KB, pdf) . The targets were predicted using the UniProt database. This analysis identified 159 putative targets, including 105 in coumarin, 10 in flavonoid, 3 in nitrogen-containing compounds, 40 in triterpenoids and 1 in ‘others.’ A compound-target network was constructed, as shown in (Fig. 3). Eventually, 57 targets for NRR against arrhythmia were obtained.

Fig. (2).

Fig. (2)

The 2-dimensional (2D) molecular structures and classification of 21 NRR candidate compounds. There were five categories including coumarin (15), triterpenoids (2), nitrogen-containing compound (1), flavonoid (1), others (2).

Fig. (3).

Fig. (3)

The construction of the compound-target network and the classification of putative target proteins of NRR compounds.

3.2. Putative NRR Target Proteins in Arrhythmia

In total, 96342 and 5584 arrhythmia-associated genes were acquired from the CTD and GeneCards databases. Following prioritized inference and relevance scores, 452 and 97 genes were identified (Tables S3 & S4). Once data from the two databases had been integrated, 265 targets remained and were considered the key putative arrhythmia-associated proteins. As shown in the Venn diagram, a total of 19 overlapping genes for NRR and arrhythmia were obtained (Fig. 4A), including CDK2, BAX, CASP3, and others, which were taken as the key targets for treating arrhythmia with NRR.

Fig. (4).

Fig. (4)

The identified genes of NRR and arrhythmia and the construction of protein-protein interaction network. (A) The overlapping genes for NRR and arrhythmia. (B) The protein-protein interaction network between NRR and arrhythmia. (C) The core module of the network. (D) The core target of the core module.

3.3. PPI Construction and Hub Genes Identification

A function-associated protein network of the interactions between NRR and arrhythmia was constructed, which included 19 nodes and 40 edges (Fig. 4B). The topological parameters were analyzed based on Analyze Network (Table S5 (659.3KB, pdf) ). Only one module was divided through MCODE, considered the core module (Fig. 4C). Furthermore, core proteins were identified via CytoHubba, including CASP3 (caspase 3), CASP8 (caspase 8), CASP9 (caspase 9), CDK2 (cell division protein kinase 2) and BAX (an apoptosis regulator BAX). These core targets all belonged to the core module (Fig. 4D).

3.4. Biological Function of NRR Targeting for Arrhythmia

In order to gain further insights into the mechanisms underlying the effect of NRR effects on arrhythmia at a systematic level, GO, and KEGG pathway analyses were carried out. There were 141 GO terms and 31 KEGG pathways enriched from the 19 overlapping targets (Tables S6 & S8), and 33 GO terms and 16 KEGG pathways enriched from 5 core targets (Tables S7 & S9). The GO-biological processes were mainly related to drug response, lipopolysaccharide and estradiol responses, the extrinsic apoptotic signaling pathway in the absence of ligands, and the apoptotic process. Fifteen pathways were consistently enriched in the overlapping and core targets. The top 3 pathways enriched by the five core targets were the p53 signaling pathway hepatitis B and apoptosis. A drug-compound-targets-pathways network was also built based on the KEGG enrichment analysis (Fig. 5).

Fig. (5).

Fig. (5)

Construction of drug-compound-target-pathway network. (wathet circle represents the herb-NRR; the pink diamond represents the compounds in NRR; the green circle represents the targets, with a green border representing core targets; the gray rectangle represents KEGG signaling enriched from 19 overlapping target proteins of NRR associated with arrhythmia, with gray border representing the KEGG pathways enriched from 5 core targets.

3.5. Molecular Docking

It is possible to predict the affinity between the two counterparts by calculating the binding energy. Ten active NRR compounds exhibiting good pharmacokinetic properties were molecularly docked with five core receptors, including CASP3 (PDBID: 1NME), CASP8 (PDBID: 2K7Z), CASP9 (PDBID: 3V3K), BAX (PDBID: 2LR1), and CDK2 (PDBID: 2R3J). A binding energy of less than 0 indicates that two molecules combine spontaneously-the lower the binding energy, the stronger the affinity of the compounds to the targets. A total of 50 ligand-receptor combinations were computed. Most NRR components could bind well with the key receptors, and 44 combinations had affinities of < -7kcal/mol, accounting for 88% of the combinations. CDK2 and C9 had the strongest binding energy, at -9.7 kcal/mol. The molecular binding results are shown in (Fig. 6). p53 signaling pathway was exhibited in (Fig. 7).

Fig. (6).

Fig. (6)

Results of molecular docking and docking simulation. (A) Heat map of the binding energies. (B) beta-sitosterol (C17) with CAS9 (PDBID: 3V3K), (C) Marmesine (C15) with CASP8 (PDBID: 2K7Z), (D) Marmesine (C15) with CDK2 (PDBID: 2R3J), (E) Marmesin (C16) with CASP8, (F) Marmesin (C16) with CDK2, and (G) Bergaptin (C9) with CDK2.

Fig. (7).

Fig. (7)

The p53 signaling pathway (KEGG database). Core receptors are shown in yellow, and other protein targets are in green.

3.6. Experimental Validation of the NRR Targets for Treating Arrhythmia

The ECG of the sham, vehicle and NRR-treated groups are shown in (Fig. 8). CASP3, CASP8, CASP9, BAX and CDK2 mRNA expression levels were all consistently altered in individual samples between the sham, vehicle and NRR groups. Expression levels of CASP3, CASP8, CASP9, BAX and CDK2 were upregulated following arrhythmia, whereas CASP3, CASP8, CASP9, BAX and CDK2 were downregulated following a 14 days NRR treatment regime.

Fig. (8).

Fig. (8)

Validation by the mRNA expression levels of CASP3, CASP8, CASP9, BAX and CDK2 using real-time RT-PCR. *P < 0.05.

4. DISCUSSION

In this study, a network pharmacology analysis was conducted on the active components of NRR in relation to arrhythmia disease targets. The ingredients contained in NRR mainly included coumarin, flavonoids, nitrogen-containing compounds, and triterpenoids, among which coumarin was the primary category. The results showed the detection of ultra-high performance liquid chromatography coupled with triple quadrupole mass spectrometry (UHPLC–MS/MS) [29]. Previous studies also verified that the aqueous solution of NRR exerts an anti-arrhythmic effect [30, 31]. The Biological processes of the NRR proteins associated with arrhythmia were involved in various apoptotic processes, such as endopeptidase activity involved in the apoptotic process by cytochrome c and in the extrinsic apoptotic signaling pathway when ligands are absent. Moreover, the p53 signaling pathway may be closely associated with mechanisms of action of the NRR proteins when it is used to treat arrhythmia.

In order to further investigate the mechanisms, module division was conducted to find the core genes using MCC in our work. CASP3, CASP8, CASP9, BAX and CDK2 were identified from the module involved in p53 signaling. In addition, molecular docking results also exhibited that these genes had good binding properties with the core target genes. Clinical studies have shown that BAX expression was increased in cardiovascular patients, including those with arrhythmia [32], and patients with caspase3 variants were susceptible to atrial fibrillation (AF) [33]. Experimental research has shown that the expression of BAX was associated with AF [34], and the disturbance balance of Bcl-2/BAX expressions may be related to the development and maintenance of AF and plays a major role in structural remodeling of the atrium [35, 36]. Myocardial apoptosis can cause electrical and structural cardiac remodeling [37], and many important apoptotic factors, such as the expression of CASP8, CASP9, and BAX in the present experiments, are altered in many cardiovascular diseases (including ischaemia/ reperfusion [38], AF [33] and ventricular fibrillation (Vf) [37]). Oxidative stress can cause apoptosis, leading to cardiac and vascular abnormalities in different types of cardiovascular disease, and its mechanism may be related to the dysregulation of the Akt/p53 signaling pathway [39]. Another experimental study indicated that pioglitazone inhibited age-related arrhythmogenic atrial remodeling and AF perpetuation by enhancing antioxidant capacity and inhibiting the mitochondrial apoptotic signaling pathway [40]. Additional studies in animal models of ventricular fibrillation have manifested that mitochondrial damage leads to activation of the mitochondrial apoptotic pathway, characterized by the release of cytochrome c into the cytoplasm, reduction of the level of CASP9, activation of CASP3 and was in line with a significant decrease in left ventricular function [41]. In summary, our findings offer new insights into future NRR research and its applications for treating arrhythmia. However, apoptosis is a complicated process multiple targets regulate that. Although our results were verified by qRT-PCR, differing components and doses needed to be assessed in future studies to understand the processes in more detail.

CONCLUSION

Here, we applied systematic pharmacology to investigate the potential mechanisms underlying the effects of NRR on arrhythmia. The analysis of modules and core nodes helped to locate the possible major functional genes. Our data has shown that NRR, especially in main components (coumarin and triterpenoids), plays an anti-apoptotic role via multiple apoptotic factors/pathways. The targets were mainly aimed at the downstream of the p53 signaling pathways, which may prove to be its mechanism against arrhythmia. Moreover, our research was previously published as a preprint at Research Square [42].

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

PVCs

Premature Ventricular Contractions

VT

Ventricular Tachycardia

TCM

Traditional Chinese Medicine

NRR

Notopterygii Rhizoma Et Radix

TCMSP

Traditional Chinese Medicine Systems Pharmacology

ETCM

Encyclopedia of Traditional Chinese Medicine

OB

Oral Bioavailability

DL

Drug-Likeness

CTD

Comparative Toxicogenomics Database

VPB

Ventricular Premature Beat

Vf

Ventricular Fibrillation

PPI

Protein-Protein Interaction

STRING

Search Tool for Recurring Instances of Neighbouring Genes

MCODE

Molecular Complex Detection

MCC

Maximal Cluque Centrality

GO

Gene Ontology

KEGG

Kyoto Encyclopedia of Genes and Genomes

DAVID

Database for Annotation, Visualization and Integrated Discovery

PDB

Protein Data Bank

ECG

Electrocardiograph

QT-PCR

Quantitative real-time Polymerase Chain Reaction

UHPLC–MS/MS

Ultra High-Performance Liquid Chromatography Coupled with Triple Quadrupole Mass Spectrometry

AF

Atrial Fibrillation

Vf

Ventricular Fibrillation

SUPPLEMENTARY MATERIALS

Supplementary material is available on the publisher’s website along with the published article.

Table S1 The 21 candidate compounds within Notopterygii Rhizoma Et Radix. Table S2 The 21 candidate compounds of Notopterygii Rhizoma Et Radix. Table S3 The 452 arrhythmia-associated Homo sapiens target proteins from the CTD analysis with an inference score of ≥50. Table S4 The 194 arrhythmia-associated Homo sapiens target proteins from the GeneCards database with an inference score of ≥30. Table S5 The topological analysis of the nodes in the PPI network. Table S6 The GO functional enrichment analysis of NRR. Table S7 The GO functional enrichment analysis of the core targets in NRR. Table S8 The KEGG pathway analysis of NRR. Table S9 The KEGG pathway analysis of the core target in NRR.

CCHTS-26-1560_SD1.pdf (659.3KB, pdf)

AUTHORS’ CONTRIBUTIONS

Hongxu Liu and Juju Shang contributed to the conception or design of the work. Wen long Xing revised the manuscript; Yupei Tan is responsible for data collection, and Penglu Wei drafted the manuscript. The final contribution was read and approved by all the authors.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

The Animal Welfare Ethics Committee of Sino Animal (Beijing) Science and Technology Development Co.Ltd reviewed and approved the animal study. (Publications No. 8023).

HUMAN AND ANIMAL RIGHTS

No animals were used. Animal experimentation was per the U.S. National Institutes of Health (NIH) guidelines.

CONSENT FOR PUBLICATION

Not applicable.

AVAILABILITY OF DATA AND MATERIALS

The datasets used and/or analysed during the current study are available from the corresponding author [JS and HL] upon reasonable request.

FUNDING

This work was supported by Grants from the National Natural Science Foundation of China (No. 81273741) and the China Postdoctoral Science Foundation (No.2021M702311).

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

REFERENCES

  • 1.Lakkireddy D., Vaseghi M. Sympathetic denervation for treatment of ventricular arrhythmias. J. Atr. Fibrillation. 2020;13(1):2404. doi: 10.4022/jafib.2404. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Markman T.M., Nazarian S. Treatment of ventricular arrhythmias: What’s New? Trends Cardiovasc. Med. 2019;29(5):249–261. doi: 10.1016/j.tcm.2018.09.014. [DOI] [PubMed] [Google Scholar]
  • 3.Dresen W.F., Ferguson J.D. Ventricular arrhythmias. Cardiol. Clin. 2018;36(1):129–139. doi: 10.1016/j.ccl.2017.08.007. [DOI] [PubMed] [Google Scholar]
  • 4.Zhang R., Zhu X., Bai H., Ning K. Network pharmacology databases for Traditional Chinese Medicine: Review and assessment. Front. Pharmacol. 2019;10:123. doi: 10.3389/fphar.2019.00123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wei M., Li H., Li Q., Qiao Y., Ma Q., Xie R., Wang R., Liu Y., Wei C., Li B., Zheng C., Sun B., Yu B. Based on network pharmacology to explore the molecular targets and mechanisms of gegen qinlian decoction for the treatment of ulcerative colitis. BioMed Res. Int. 2020;2020:1–18. doi: 10.1155/2020/5217405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Xu J., Wang F., Guo J., Xu C., Cao Y., Fang Z., Wang Q. Pharmacological mechanisms underlying the neuroprotective effects of Alpinia oxyphylla Miq. on Alzheimer’s disease. Int. J. Mol. Sci. 2020;21(6):2071. doi: 10.3390/ijms21062071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Pharmacopoeia of the People’s Republic of China. Beijing: China Medical Science and Technology Press; 2015. Chinese Pharmacopoeia Commission. pp. 182–183. [Google Scholar]
  • 8.Hong L., Juanjuan Z., Xiaoxiang Z., Wei W. Therapeutical effect of Radix aconiti and Astragalus extracts on models of experimental bradycardia animal. Pak. J. Pharm. Sci. 2014;27(3):439–444. doi: 10.1016/j.drudis.2014.01.001. [DOI] [PubMed] [Google Scholar]
  • 9.Guo P., Lang Y.J., Zhang G.T. Research progress on chemical constituents and pharmacological activities of Notopterygii Rhizoma et Radix. Zhongchengyao. 2019;41(10):2445–2459. doi: 10.3969/j.issn.1001-1528.2019.10.033. [DOI] [Google Scholar]
  • 10.Gong Z.H., Duan Y.Q., Fu X.Y., Ma J., Wang L.Y., Bai M. Study on pharmacological mechanisms of Notopterygii Rhizoma et Radix. Asia-Pacific Tradit Med. 2019;15(5):192–194. doi: 10.11954/ytctyy.201905061. [DOI] [Google Scholar]
  • 11.Ma L.M., Yang J.L. Research progress on chemical constituents and pharmacological activities of Notopterygii Rhizoma et Radix. Chin. Tradit. Herbal Drugs. 2021;52(19):6111–6120. doi: 10.7501/j.issn.0253-2670.2021.19.034. [DOI] [Google Scholar]
  • 12.Sinatra L., Bandolik J.J., Roatsch M., Sönnichsen M., Schoeder C.T., Hamacher A., Schöler A., Borkhardt A., Meiler J., Bhatia S., Kassack M.U., Hansen F.K. Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of dual‐targeting HDAC inhibitors and HDAC degraders (PROTACs). Angew. Chem. Int. Ed. 2020;59(50):22494–22499. doi: 10.1002/anie.202006725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Wong D.P., Roy N.K., Zhang K., Anukanth A., Asthana A., Shirkey-Son N.J., Dunmire S., Jones B.J., Lahr W.S., Webber B.R., Moriarity B.S., Caimi P., Parameswaran R. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers. Nat. Commun. 2022;13(1):217. doi: 10.1038/s41467-021-27853-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Batool M., Ahmad B., Choi S. A structure-based drug discovery paradigm. Int. J. Mol. Sci. 2019;20(11):2783. doi: 10.3390/ijms20112783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Parker C.G., Galmozzi A., Wang Y., Correia B.E., Sasaki K., Joslyn C.M., Kim A.S., Cavallaro C.L., Lawrence R.M., Johnson S.R., Narvaiza I., Saez E., Cravatt B.F. Ligand and target discovery by fragment-based screening in human cells. Cell. 2017;168(3):527–541.e29. doi: 10.1016/j.cell.2016.12.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Xie T., Song S., Li S., Ouyang L., Xia L., Huang J. Review of natural product databases. Cell Prolif. 2015;48(4):398–404. doi: 10.1111/cpr.12190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Yu W., MacKerell A.D. Jr Computer-aided drug design methods. Methods Mol. Biol. 2017;1520:85–106. doi: 10.1007/978-1-4939-6634-9_5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Zhong F., Xing J., Li X., Liu X., Fu Z., Xiong Z., Lu D., Wu X., Zhao J., Tan X., Li F., Luo X., Li Z., Chen K., Zheng M., Jiang H. Artificial intelligence in drug design. Sci. China Life Sci. 2018;61(10):1191–1204. doi: 10.1007/s11427-018-9342-2. [DOI] [PubMed] [Google Scholar]
  • 19.Huang K., Zhang P., Zhang Z., Youn J.Y., Wang C., Zhang H., Cai H. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms. Pharmacol. Ther. 2021;225:107843. doi: 10.1016/j.pharmthera.2021.107843. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Mo S.L., Liu W.F., Chen Y., Luo H.B., Sun L.B., Chen X.W., Zhou Z.W., Sneed K.B., Li C.G., Du Y.M., Liang J., Zhou S.F. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin, Baikal Skullcap). Comb. Chem. High Throughput Screen. 2012;15(1):36–80. doi: 10.2174/138620712798280826. [DOI] [PubMed] [Google Scholar]
  • 21.Ru J., Li P., Wang J., Zhou W., Li B., Huang C., Li P., Guo Z., Tao W., Yang Y., Xu X., Li Y., Wang Y., Yang L. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform. 2014;6(1):13. doi: 10.1186/1758-2946-6-13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wu Y., Zhang F., Yang K., Fang S., Bu D., Li H., Sun L., Hu H., Gao K., Wang W., Zhou X., Zhao Y., Chen J. SymMap: An integrative database of traditional Chinese medicine enhanced by symptom mapping. Nucleic Acids Res. 2019;47(D1):D1110–D1117. doi: 10.1093/nar/gky1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Xu H.Y., Zhang Y.Q., Liu Z.M., Chen T., Lv C.Y., Tang S.H., Zhang X.B., Zhang W., Li Z.Y., Zhou R.R., Yang H.J., Wang X.J., Huang L.Q. ETCM: An encyclopaedia of traditional Chinese medicine. Nucleic Acids Res. 2019;47(D1):D976–D982. doi: 10.1093/nar/gky987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Davis A.P., Grondin C.J., Johnson R.J., Sciaky D., McMorran R., Wiegers J., Wiegers T.C., Mattingly C.J. The comparative toxicogenomics database: Update 2019. Nucleic Acids Res. 2019;47(D1):D948–D954. doi: 10.1093/nar/gky868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Stelzer G., Rosen N., Plaschkes I. The genecards suite: From gene data mining to disease genome sequence analyses. Curr. Protoc. Bioinform. 2016;54(1):1.30.1–1.30.33. doi: 10.1002/cpbi.5. [DOI] [PubMed] [Google Scholar]
  • 26.Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., Amin N., Schwikowski B., Ideker T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi: 10.1101/gr.1239303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009;4(1):44–57. doi: 10.1038/nprot.2008.211. [DOI] [PubMed] [Google Scholar]
  • 28.Huang D.W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: Paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13. doi: 10.1093/nar/gkn923. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Wu X.W., Zhang Y.B., Zhang L., Yang X.W. Simultaneous quantification of 33 active components in Notopterygii Rhizoma et Radix using ultra high performance liquid chromatography with tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2018;1092:244–251. doi: 10.1016/j.jchromb.2018.06.006. [DOI] [PubMed] [Google Scholar]
  • 30.Ma Y.L., Lin J.M., Ma L., Zhang C. Progress in researches on notopterygium. Anhui Nongye Kexue. 2010;38(24):13092–13093. doi: 10.13989/j.cnki.0517-6611.2010.24.095. [DOI] [Google Scholar]
  • 31.Cheng Y.Z., Shan Z.Y., Chen Y.P. Comparison of antiarrhythmic effects of different components of Qianghuishui solution. J. Basic Clin. Med. 1998;4(2):43. [Google Scholar]
  • 32.Mohammadi A., Balizadeh Karami A.R., Dehghan Mashtani V., Sahraei T., Bandani Tarashoki Z., Khattavian E., Mobarak S., Moradi Kazerouni H., Radmanesh E. Evaluation of oxidative stress, apoptosis, and expression of MicroRNA-208a and MicroRNA-1 in cardiovascular patients. Rep. Biochem. Mol. Biol. 2021;10(2):183–196. doi: 10.52547/rbmb.10.2.183. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Luo Z., Yan C., Yu P., Bao W., Shen X., Zheng W., Lin X., Wang Z., Chen H., Chen F., Liu D., Huang M. CASP3 genetic variants and susceptibility to atrial fibrillation in Chinese Han population. Int. J. Cardiol. 2015;183:1–5. doi: 10.1016/j.ijcard.2015.01.048. [DOI] [PubMed] [Google Scholar]
  • 34.Li Y., Song B., Xu C. Effects of Guanfu total base on Bcl-2 and Bax expression and correlation with atrial fibrillation. Hellenic J. Cardiol. 2018;59(5):274–278. doi: 10.1016/j.hjc.2018.02.009. [DOI] [PubMed] [Google Scholar]
  • 35.Diao S.L., Xu H.P., Zhang B., Ma B.X., Liu X.L. Associations of MMP-2, BAX, and Bcl-2 mRNA and protein expressions with development of atrial fibrillation. Med. Sci. Monit. 2016;22:1497–1507. doi: 10.12659/MSM.895715. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Xu G.J., Gan T.Y., Tang B.P., Chen Z.H., Mahemuti A., Jiang T., Song J.G., Guo X., Li Y.D., Miao H.J., Zhou X.H., Zhang Y., Li J.X. Accelerated fibrosis and apoptosis with ageing and in atrial fibrillation: Adaptive responses with maladaptive consequences. Exp. Ther. Med. 2013;5(3):723–729. doi: 10.3892/etm.2013.899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Zhan C., Liu G., Li J., Li G., Li T., Zhao H., Li L., Yang W., Bai N., Zheng M., Yang J., Li W. Rotenone and 3-bromopyruvate toxicity impacts electrical and structural cardiac remodeling in rats. Toxicol. Lett. 2020;318:57–64. doi: 10.1016/j.toxlet.2019.09.024. [DOI] [PubMed] [Google Scholar]
  • 38.Zhang J., Zhang X. Ischaemic preconditioning‐induced serum exosomes protect against myocardial ischaemia/reperfusion injury in rats by activating the PI3K/AKT signalling pathway. Cell Biochem. Funct. 2021;39(2):287–295. doi: 10.1002/cbf.3578. [DOI] [PubMed] [Google Scholar]
  • 39.Zheng N., Li H., Wang X., Zhao Z., Shan D. Oxidative stress-induced cardiomyocyte apoptosis is associated with dysregulated Akt/p53 signaling pathway. J. Recept. Signal Transduct. Res. 2020;40(6):599–604. doi: 10.1080/10799893.2020.1772297. [DOI] [PubMed] [Google Scholar]
  • 40.Xu D., Murakoshi N., Igarashi M., Hirayama A., Ito Y., Seo Y., Tada H., Aonuma K. PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. J. Cardiovasc. Electrophysiol. 2012;23(2):209–217. doi: 10.1111/j.1540-8167.2011.02186.x. [DOI] [PubMed] [Google Scholar]
  • 41.Ayoub I.M., Radhakrishnan J., Gazmuri R.J. Targeting mitochondria for resuscitation from cardiac arrest. Crit. Care Med. 2008;36(11):S440–S446. doi: 10.1097/CCM.0b013e31818a89f4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Wei P.L., Qi Y.F., Tan Y.P., Long D.H., Xing W.L. Molecular mechanisms of Notopterygii Rhizoma Et radix for the treatment of arrhythmia based on network pharmacology. Res. Sqare; 2021. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary material is available on the publisher’s website along with the published article.

Table S1 The 21 candidate compounds within Notopterygii Rhizoma Et Radix. Table S2 The 21 candidate compounds of Notopterygii Rhizoma Et Radix. Table S3 The 452 arrhythmia-associated Homo sapiens target proteins from the CTD analysis with an inference score of ≥50. Table S4 The 194 arrhythmia-associated Homo sapiens target proteins from the GeneCards database with an inference score of ≥30. Table S5 The topological analysis of the nodes in the PPI network. Table S6 The GO functional enrichment analysis of NRR. Table S7 The GO functional enrichment analysis of the core targets in NRR. Table S8 The KEGG pathway analysis of NRR. Table S9 The KEGG pathway analysis of the core target in NRR.

CCHTS-26-1560_SD1.pdf (659.3KB, pdf)

Data Availability Statement

The datasets used and/or analysed during the current study are available from the corresponding author [JS and HL] upon reasonable request.


Articles from Combinatorial Chemistry & High Throughput Screening are provided here courtesy of Bentham Science Publishers

RESOURCES